Ekso Bionics

• EksoNR

  EksoNR

• EKSO - NASDAQ - USD

• Rachael Anderson - Vice President of Sales, North America - Anderson leads North American sales for Ekso Bionics rehabilitation and exoskeleton products.
• Stephan Aderhold - Senior Vice President & General Manager, EMEA - Aderhold leads Ekso Bionics EMEA commercial operations for exoskeleton and rehabilitation markets.
• Jason Jones - Chief Operating Officer - Jones leads operating execution for Ekso Bionics wearable robotics and rehabilitation exoskeleton programs.
• Jerome Wong - Chief Financial Officer - Wong leads Ekso Bionics finance, reporting, budgeting, treasury, and investor-relations support.
• Scott Davis - CEO - Davis leads Ekso Bionics rehabilitation and exoskeleton robotics business.

Events

• 2026-10-01 - Acquisition - Wandercraft completes acquisition of Ekso Bionics operating business

  Atalante X and EksoNR together support patients at more than 700 rehabilitation centers worldwide. Wandercraft intends to keep supporting Atalante X, EksoNR, Eve and Indego Personal. Both boards unanimously approved the transaction, combining Wandercraft’s EMEA position with Ekso’s U.S. clinical and commercial reach.

  Source
• 2026-01-21 - Regulatory - Ekso Bionics prices $5.852 million private placement

  Ekso Bionics announced a private placement expected to generate gross proceeds of approximately $5.852 million before fees and expenses. The company said the financing would support working capital and general corporate purposes as it continued commercializing exoskeleton products for medical and industrial use. The event followed a difficult 2025 operating year and served as a balance-sheet support step rather than a product milestone.

  Source
• 2025-12-04 - Partnership - Ekso Bionics inks agreement to become the exclusive U.S. distributor of MediTouch BalanceTutor

  Ekso Bionics signed an agreement to become the exclusive U.S. distributor of MediTouch''s BalanceTutor rehabilitation system. The deal broadened Ekso''s rehabilitation portfolio beyond exoskeletons into balance and fall-prevention training hardware for clinics. Ekso framed the agreement as a commercial expansion step into adjacent rehabilitation categories rather than a pure internal product launch.

  Source
• 2025-10-29 - Regulatory - Ekso Bionics announces $3.7 million registered direct offering

  Ekso Bionics entered into a definitive agreement with institutional investors for a registered direct offering expected to raise approximately $3.7 million in gross proceeds. The offering was priced at-the-market under Nasdaq rules and consisted of 769,490 shares of common stock at $4.81 per share. The raise functioned as financing support for ongoing operations and commercialization rather than a strategic partnership or product event.

  Source
• 2025-06-18 - Demonstration - Ekso Bionics demonstrates early AI voice-agent proof of concept following NVIDIA Connect acceptance

  Ekso Bionics announced an early proof of concept for an AI voice agent designed to support operation, motivation, training, and safety around its exoskeleton devices. The company said the demo came just over a month after entering the NVIDIA Connect program and tied the initiative to its broader strategy to build AI capabilities across its rehabilitation platforms. The proof of concept was framed as an initial software capability milestone rather than a commercial product release.

  Source
• 2025-05-15 - Partnership - Ekso Bionics accepted into NVIDIA Connect program for rehabilitation AI initiative

  Ekso Bionics said it had been accepted into the NVIDIA Connect program as part of a strategic initiative to build what it described as the first known foundation model for human motion in physical rehabilitation. The company tied the partnership to future integration of AI capabilities across its Enterprise Health and Personal Health exoskeleton portfolio. The announcement marked a software and ecosystem expansion step layered on top of Ekso''s wearable robotics hardware business.

  Source
• 2025-04-23 - Partnership - Bionic P&O chosen as first distributor of Ekso Indego Personal in the U.S. orthotics and prosthetics market

  Ekso Bionics named Bionic Prosthetics & Orthotics Group as a non-exclusive distributor for the Ekso Indego Personal device. The company said the alliance marked its first entrance into the orthotics and prosthetics channel for the personal exoskeleton business. The event expanded Ekso''s commercial route to market for personal mobility devices rather than introducing a new hardware platform.

  Source
• 2025-03-18 - Partnership - Ekso Bionics names National Seating & Mobility exclusive U.S. CRT distributor for Ekso Indego Personal

  Ekso Bionics named National Seating & Mobility as the exclusive U.S. distributor of Ekso Indego Personal within the complex rehabilitation technology channel. The company said the agreement broadened access to the personal exoskeleton through a national mobility-solutions network. The event represented a commercial distribution expansion for a core personal-health product line rather than a new device launch.

  Source
• 2020-06-15 - Regulatory - EksoNR receives FDA clearance for acquired brain injury rehabilitation

  The clearance expanded EksoNR beyond earlier stroke and spinal cord injury indications. The system is a robotic exoskeleton used in clinical rehabilitation settings. The approval supports EksoNR's path toward fielded use in robot manipulation, haptics or human-assistive robotics workflows.

  Source

Relationships

• NVIDIA

  Nvidia Connect / AI Ecosystem - Accepted into NVIDIA Connect program for rehabilitation AI and foundation-model initiative.

• MediTouch

  Balancetutor U.s. Distribution - Exclusive U.S. distributor agreement for MediTouch BalanceTutor rehabilitation system.

• Bionic Prosthetics & Orthotics Group

  Indego Personal Distributor (o&p) - Bionic Prosthetics & Orthotics Group named non-exclusive U.S. distributor for Ekso Indego Personal in O&P channel.

• National Seating & Mobility

  Indego Personal Distributor (crt) - National Seating & Mobility named exclusive U.S. CRT distributor for Ekso Indego Personal.

• Wandercraft

  Acquired Company - Wandercraft acquired the Ekso Bionics operating business from a ChronoScale Holdings subsidiary in a signed-and-closed transaction.

• Parker Hannifin

  Acquired Indego Product Business - Ekso Bionics acquired Parker Hannifin's Indego exoskeleton business in 2022, including its products and clinical relationships.

Comparable profiles

• Hypershell

  comparable profile

• CYBERDYNE

  comparable profile - Medical Exoskeletons

• Chengtian Technology (程天科技)

  comparable profile - Medical Exoskeletons

• Wandercraft

  comparable profile - Medical Exoskeletons

• Fourier Intelligence

  comparable profile - Medical Exoskeletons

• Wearable Robotics

  comparable profile - Medical Exoskeletons

Shared workflows

• Marsi Bionics

  workflow adjacency - Rehabilitation Robotics

• Trexo Robotics

  workflow adjacency - Rehabilitation Robotics

• REEV

  workflow adjacency - Rehabilitation Robotics

• Reactive Robotics

  workflow adjacency - Rehabilitation Robotics

• Human Robotix

  workflow adjacency - Rehabilitation Robotics

• Humotech

  workflow adjacency - Rehabilitation Robotics

Context tags

• Rehabilitation robotics platform - Stack Layer - Ekso provides rehabilitation exoskeleton platforms.
• Medical exoskeletons - Peer Group - EksoNR and EksoUE are powered medical exoskeleton systems.
• Gait rehabilitation - Workflow - EksoNR supports gait rehabilitation and walking recovery.
• Powered limb assistance - Capability - Ekso exoskeletons provide powered limb assistance for impaired mobility.
• Rehabilitation robotics workflow - Workflow - Ekso develops rehabilitation exoskeletons for gait training and mobility.
• Medical robot OEM - Stack Layer - Ekso builds complete powered exoskeleton robot systems.
• Rehabilitation clinics - Customer Environment - Ekso exoskeletons are used in rehabilitation clinics.
• Home assistive care - Customer Environment - Ekso exoskeletons support community and home mobility use.